Gary Brecka Testifies as FDA Panel Narrowly Backs Compounded Peptides

Gary Brecka took his longevity advocacy from the podcast studio to a federal hearing room this week, testifying before an FDA advisory committee that narrowly voted to loosen restrictions on compounded peptides.

What the panel decided

Over two days of meetings on July 23 and 24, the FDA's Pharmacy Compounding Advisory Committee weighed whether seven popular peptides should be added to the 503A bulks list, which would let compounding pharmacies legally produce them. The panel voted narrowly in favor for most of the compounds, including BPC-157, TB-500 and KPV, with one vote reported at 8-6 with an abstention. Epitalon was backed while emideltide was rejected. The votes are recommendations, not final rules, and the FDA is not obligated to follow them.

Brecka's role

Brecka, host of The Ultimate Human podcast and a co-chair of the MAHA Action committee, gave testimony at the hearing in favor of broader peptide access. The vote is widely described as a win for HHS Secretary Robert F. Kennedy Jr., who has promoted peptides as part of his agenda. Brecka has been one of the most visible non-clinician voices in that push.

The criticism

The recommendation drew objections from the FDA's own scientists and from outside researchers, who argue these peptides lack the controlled human trial data that approval normally requires. Critics have described the current peptide market as a largely unregulated space where infection, allergic reaction and contamination are real risks. Coverage has also noted that Brecka sells peptide products through his own businesses, which supporters view as domain expertise and critics view as a conflict of interest.

Why it matters

If the FDA adopts the committee's recommendations, compounded peptides would move from a legal gray zone into pharmacy shelves, a meaningful shift for the longevity and wellness industry. For readers, the practical takeaway is unchanged for now: the underlying evidence for most of these compounds remains thin, and anyone considering them should be working with a physician rather than a podcast.